Katarina Ejeskär

823 citations

35 papers · 593 indexed · h-index 16

Impact in

Neurology top 5%
- Neuroblastoma Research and Treatments
Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism

Papers in

Neurology 21
- Neuroblastoma Research and Treatments 21
Cancer Research 15
- Cancer, Hypoxia, and Metabolism 14

Co-authors: Tommy Martinsson Per Kogner Frida Abel Susanne Fransson Cecilia Krona Helena Carén Jonas Abrahamsson Hiroyuki Aburatani
Journals: British Journal of Cancer (5 papers)BMC Cancer (2 papers)International Journal of Molecular Medicine (2 papers)Oncogene (2 papers)PLoS ONE (2 papers)
Partner nations: Sweden Australia Spain

In The Last Decade

Katarina Ejeskär

35 papers receiving 585 citations

Peers

Countries citing papers authored by Katarina Ejeskär

Since Specialization

Citations

This map shows the geographic impact of Katarina Ejeskär's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katarina Ejeskär with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katarina Ejeskär more than expected).

Fields of papers citing papers by Katarina Ejeskär

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katarina Ejeskär. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katarina Ejeskär. The network helps show where Katarina Ejeskär may publish in the future.

Co-authors

The 25 scholars most cited alongside Katarina Ejeskär, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katarina Ejeskär Line = papers co-authored together Katarina Ejeskär links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Increased MLH1 , MGMT , and p16INK4a methylation levels in colon mucosa potentially useful as early risk marker of colon cancer Molecular & Cellular Oncology ·Yvonne Wettergren, P. Rolny, Pere Reixach, Elisabeth Odin, Victoria Rotter Sopasakis, H. Hannah Inbarani, Katarina Ejeskär	2025	2
2	DLG2 impairs dsDNA break repair and maintains genome integrity in neuroblastoma DNA repair ·H. Hannah Inbarani, A. S. Medvedev, Katarina Ejeskär	2022	7
3	Inflammation suppresses DLG2 expression decreasing inflammasome formation Journal of Cancer Research and Clinical Oncology ·H. Hannah Inbarani, Matthew P. Herring, P. Rolny, Yvonne Wettergren, Katarina Ejeskär	2022	16
4	Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib Cancer Biology & Therapy ·J-E Dubuc, H. Hannah Inbarani, Thomas Olsson Bontell, Helene Sjögren, Henrik Fagman, Ingrid Øra, 重明諏訪, Magnus Tisell, Jonas A. Nilsson, Katarina Ejeskär, Magnus Sabel, Frida Abel	2021	8
5	The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma Cancer Cell International ·H. Hannah Inbarani, Tommy Martinsson, Per Kogner, Katarina Ejeskär	2021	3
6	MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression PLoS Genetics ·Tajana Tešan Tomić, Samanta Galluzzi, Liliane Cristina da Silva Camargo, J-E Dubuc, Andreas Muth, Katarina Ejeskär, Staffan Nilsson, Erik Kristiansson, 윤호범, Frida Abel	2020	17
7	Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT PLoS ONE ·Kanan Tooru, 党珍, Gyorgy Pravecz, Iman van den Bout, Charlotte Örndal, Janusz Marcickiewicz, Staffan Nilsson, Michael Hörnquist, Björn Olsson, Katarina Ejeskär, Afrouz Behboudi	2016	15
8	Verification of microRNA expression in human endometrial adenocarcinoma BMC Cancer ·Nobutaka Okino, Karin Klinga‐Levan, Björn Olsson, Katarina Ejeskär	2016	24
9	The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo PLoS ONE ·Katarina Ejeskär, Shaweta Kaundal, J. Zeng, Yvonne Wettergren, Anne Uv, Victoria Rotter Sopasakis	2015	2
10	Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas PubMed ·Susanne Fransson, Per Kogner, Tommy Martinsson, Katarina Ejeskär	2013	4
11	High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival Medical Oncology ·Susanne Fransson, Katarina Ejeskär	2013	6
12	p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors Oncogene ·Susanne Fransson, Anne Uv, Helena Eriksson, Mattias K. Andersson, Yvonne Wettergren, Martin O. Bergö, Katarina Ejeskär	2011	19
13	Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death BMC Cancer ·Katarina Ejeskär, Cecilia Krona, Helena Carén, ROSWITH L. ROTH, Lingli Li, Tommy Martinsson, Panayiotis A. Ioannou	2005	57
14	A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Molecular Cancer ·Helena Carén, Katarina Ejeskär, Susanne Fransson, Luke B. Hesson, Farida Latif, Rose‐Marie Sjöberg, Cecilia Krona, Tommy Martinsson	2005	27
15	A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours British Journal of Cancer ·Cecilia Krona, Katarina Ejeskär, Helena Carén, Frida Abel, 于慧春, Tommy Martinsson	2004	14
16	Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2 Oncogene ·Cecilia Krona, Katarina Ejeskär, Frida Abel, Per Kogner, B. Ersoy, 石育斌, Rose‐Marie Sjöberg, Tommy Martinsson	2003	45
17	Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours British Journal of Cancer ·Frida Abel, 于慧春, Katarina Ejeskär, Cecilia Krona, Tommy Martinsson	2002	33
18	Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3→p36.2, but absence of mutations in primary tumors Cytogenetic and Genome Research ·Katarina Ejeskär, Frida Abel, ゆか理渡邉, J.R. Backstrom, Per Kogner, Tommy Martinsson	2000	28
19	Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development. International Journal of Molecular Medicine ·Katarina Ejeskär, ゆか理渡邉, Per Kogner, Tommy Martinsson	1999	18
20	Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene British Journal of Cancer ·Katarina Ejeskär, Hiroyuki Aburatani, Jonas Abrahamsson, Per Kogner, Tommy Martinsson	1998	55

About Katarina Ejeskär

Katarina Ejeskär is a scholar working on Neurology, Cancer Research, Aging, Molecular Biology and Oncology, having authored 35 papers that have together received 593 indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (21 papers), Cancer, Hypoxia, and Metabolism (14 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Neuroendocrine Tumor Research Advances (4 papers), Cell death mechanisms and regulation (4 papers), Virus-based gene therapy research (3 papers), Muscle Physiology and Disorders (3 papers) and Ubiquitin and proteasome pathways (3 papers). The work is most often cited by research in Neurology (223 citations), Cancer Research (188 citations), Molecular Biology (400 citations), Oncology (125 citations) and Genetics (32 citations). Katarina Ejeskär has collaborated with scholars based in Sweden, Australia and Spain. Frequent co-authors include Tommy Martinsson, Per Kogner, Frida Abel, Susanne Fransson, Cecilia Krona, Helena Carén, Jonas Abrahamsson, Hiroyuki Aburatani, Panayiotis A. Ioannou and Rose‐Marie Sjöberg. Their work appears in journals such as British Journal of Cancer, BMC Cancer, International Journal of Molecular Medicine, Oncogene and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact